170 related articles for article (PubMed ID: 32453080)
1. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
Michalski K; Laubner K; Stoykow C; Omrane MA; Maecke HR; Seufert J; Goetz C; Meyer PT; Ruf J
Clin Nucl Med; 2020 Jul; 45(7):519-524. PubMed ID: 32453080
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.
Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E
J Clin Endocrinol Metab; 2019 Dec; 104(12):5843-5852. PubMed ID: 31298706
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
4. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
5. Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.
Antwi K; Nicolas G; Fani M; Christ E; Wild D
Clin Nucl Med; 2019 May; 44(5):e347-e348. PubMed ID: 30889001
[TBL] [Abstract][Full Text] [Related]
6. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia.
Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK
Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
8.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
9. Utility of
Kalff V; Iravani A; Akhurst T; Pattison DA; Eu P; Hofman MS; Hicks RJ
Intern Med J; 2021 Oct; 51(10):1657-1664. PubMed ID: 33314504
[TBL] [Abstract][Full Text] [Related]
10. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
12. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.
Pallavi UN; Malasani V; Sen I; Thakral P; Dureja S; Pant V; Gaikwad VS; Sabharwal A
Indian J Nucl Med; 2019; 34(1):14-18. PubMed ID: 30713372
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
Sood A; Basher RK; Kang M; Shukla J; Behera A; Walia R; Nada R; Mittal BR; Bhattacharya A
Clin Nucl Med; 2019 Jul; 44(7):e428-e430. PubMed ID: 31107750
[TBL] [Abstract][Full Text] [Related]
16. Early
Leroy-Freschini B; Amodru V; Addeo P; Sebag F; Vix M; Brunaud L; Klein M; Bahougne T; Bachellier P; Castinetti F; Goichot B; Chevalier E; Taieb D; Imperiale A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):686-695. PubMed ID: 30617961
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
18. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
19. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M
Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.
Garg R; Shah R; Tiwari A; Purandare N; Lele VR; Malhotra G; Verma P; Gosavi V; Dalvi A; Kumar Jaiswal S; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2020 Dec; 93(6):678-686. PubMed ID: 32716527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
